advertisement
Abstract #75108 Published in IGR 19-2
Severe Corneal Disorders Developed After Brimonidine Tartrate Ophthalmic Solution Use
Maruyama Y; Ikeda Y; Yokoi N; Mori K; Kato H; Ueno M; Kinoshita S; Sotozono CCornea 2017; 36: 1567-1569
PURPOSE: The primary side effects associated with 0.1% brimonidine tartrate (BT) ophthalmic solution with sodium chlorite are allergic conjunctivitis, blepharitis, and conjunctival hyperemia. However, cornea-related side effects are rare. In this study, we report 2 similar cases in which corneal neovascularization, corneal infiltration, and corneal opacity developed after BT eye-drop use. METHODS: Retrospective report of 2 cases of corneal infiltration after BT eye-drop use. RESULTS: Case 1 involved a 78-year-old woman with follicular conjunctivitis, corneal neovascularization, and infiltration in her left eye after unilateral instillation of BT eye drops in that eye. Case 2 involved a 75-year-old woman with bilateral corneal neovascularization and infiltration after instillation of BT eye drops. In both cases, the corneal complications were deemed to be side effects of BT, so those eye drops were replaced with 0.1% fluorometholone eye drops. After replacement, blepharitis and corneal neovascularization successfully resolved; however, a layer of opacity remained across the transparent layer of the cornea in both cases. CONCLUSIONS: We encountered 2 cases of corneal and conjunctival complications that developed as side effects after BT eye-drop use, thus indicating that strict attention should be paid to the possibility of side effects after initiation of antiglaucoma eye-drop use.
*Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan; †Department of Ophthalmology, Fukuchiyama City Hospital, Kyoto, Japan; ‡Oike-Ganka Ikeda Clinic, Kyoto, Japan; §Department of Ophthalmology, National Center for Geriatrics and Gerontology, Obu, Japan; and ¶Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Full articleClassification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
2.2 Cornea (Part of: 2 Anatomical structures in glaucoma)